Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 9.768
- Book/Share 2.5668
- PB 15.5253
- Debt/Equity 1.9244
- CurrentRatio 1.8751
- ROIC 0.0638
- MktCap 8737945006.0
- FreeCF/Share 0.5811
- PFCF 66.4296
- PE 67.419
- Debt/Assets 0.5006
- DivYield 0
- ROE 0.2467
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | HIMS | KeyBanc Capital Markets | -- | Sector Weight | -- | -- | Oct. 21, 2025 |
| Downgrade | HIMS | Needham | Buy | Hold | -- | -- | June 23, 2025 |
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
HIMS vs. GDRX: Which Consumer Health Stock Offers Greater Upside?
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers and GoodRx are reshaping virtual care, but which one leads in platform strategy and patient engagement? Let's dive in.
Read More
From Hair Loss To GLP-1: Hims & Hers Health Is Quietly Building A 2030 Healthcare Platform
Published: November 25, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health, Inc. (HIMS) presents a compelling risk-reward profile as bearish sentiment and regulatory concerns appear fully priced into the stock. HIMS is aggressively expanding its product offerings and logistics, driving subscriber and revenue growth, despite near-term margin compression and increased capital expenditures. The upcoming Zava acquisition and potential regulatory changes could further boost HIMS's international presence and revenue, with DCF-based valuations suggesting significant upside.
Read More
Hims & Hers Expands Care Scope as Digital Health Platforms Evolve
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS expands into low testosterone and menopause care, with plans for longevity and global growth in 2026.
Read More
Hims & Hers Accelerates Its Clinician-Led, Platform-Driven Care Model
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its connected care model with new diagnostics, hormonal health services and at-home testosterone treatments.
Read More
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical Info Systems sector might want to consider either Omnicell (OMCL) or Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Hims & Hers Plunges 15.6% in 3 Months: Time to Hold the Stock or Sell?
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
HIMS faces rising regulatory strain, margin pressure and competition despite strong revenue momentum.
Read More
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Read More
Il Makiage parent Oddity takes aim at Hims with new telehealth skincare platform Methodiq
Published: November 18, 2025 by: CNBC
Sentiment: Positive
Oddity, the maker of Il Makiage and Spoiled Child, launched its third brand Methodiq, a telehealth platform for medical skincare. Methodiq will offer 28 new products, including creams, supplements and cosmetics, that address acne, hyperpigmentation and eczema and range in price from about $29 to around $59.
Read More
Hims & Hers Bets on Lab Testing to Boost Growth
Published: November 13, 2025 by: WSJ
Sentiment: Positive
The telehealth platform expects the new offering to add to its user base as it draws customers looking to prevent future health issues.
Read More
Hims & Hers Scales Technology-Enabled, Vertically Integrated Care
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
HIMS deepens its technology-enabled care model with new offerings in GLP-1 weight loss, hormone health, and custom treatments.
Read More
3 Overvalued Stocks to Sell
Published: November 11, 2025 by: Morningstar
Sentiment: Negative
These are among the most overvalued stocks that Morningstar covers.
Read More
Hims & Hers: Fast-Fashion Healthcare Is The Future (Rating Upgrade)
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Positive
We're turning bullish on Hims & Hers now that we believe the worst is priced in. Q3 results confirm that the growth story remains centered around personalized plans driving 50% Y/Y revenue growth. Hence, it see longer-term financial leverage from scaling that business model. The "active discussions" with Novo Nordisk are a cherry on top but we see green shoots outside of weight-loss drugs that'll support growth.
Read More
Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its AI-powered, subscription-based care model globally, backed by $870 million in fresh funding for growth.
Read More
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Hims & Hers Stock Slips Post Y/Y Q3 Earnings Decline, Margins Contract
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
HIMS reports lower third-quarter 2025 earnings even as revenue and subscriber growth remain strong across its channels.
Read More
Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results
Published: November 05, 2025 by: MarketBeat
Sentiment: Neutral
Hims & Hers Health Inc. NYSE: HIMS stock is holding onto a slight gain the day after the company delivered a mixed third-quarter earnings report. The caution centers around the company's valuation, which makes it an outlier among healthcare stocks.
Read More
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Hims & Hers Scales AI-Driven Personalized Health and Wellness
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS scales AI-driven care with new hormonal health lines, global expansion plans and a $870 million funding boost.
Read More
Struggling Healthcare Stock Ripe For Bull Notes
Published: October 30, 2025 by: Forbes
Sentiment: Positive
Shares of Hims & Hers Health (HIMS) are headed for their fourth-straight daily drop, down 2.4% to trade at $45.53 at last check, as investors look ahead to the company's third quarter results, due out after the close Monday, Nov. 3. Since hitting a February record high of $72.98, the stock has staged several rallies that have run out of steam around $65.
Read More
LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc.
Published: October 29, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 29, 2025 /PRNewswire/ -- A securities fraud class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) is pending. The lawsuit was filed by Glancy Prongay & Murray LLP.
Read More
Can Sustained Product Demand Drive HIMS Stock Before Q3 Earnings?
Published: October 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers benefits from strong platform engagement and hormonal health launches ahead of third-quarter 2025 earnings.
Read More
HIMS vs. LFMD: Which Telehealth Stock Is the Better Investment Now?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers and LifeMD are reshaping virtual care, but which one leads in earnings growth and platform scale? Let's dive in.
Read More
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
Hims & Hers Health (HIMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Hims & Hers Short Interest Nears All-Time High, Buy The Dip?
Published: October 24, 2025 by: MarketBeat
Sentiment: Positive
Shares of Hims & Hers Health Inc. NYSE: HIMS have been the hottest thing in the medical sector, and for good reason. The company's fundamentals are highly attractive for investors who prefer to acquire growth stories early, before they become too large to price in further expansion.
Read More
Telehealth Stock Could Rebound Off Long-Term Trendline
Published: October 23, 2025 by: Schaeffers Research
Sentiment: Neutral
Telehealth stock Hims & Hers Health Inc (NYSE:HIMS) just suffered a steep pullback after President Donald Trump's said Novo Nordisk's (NVO) weight-loss and diabetes drugs , Wegovy and Ozempic, should be reduced to $150 a month.
Read More
Hims & Hers Advances AI-Powered Personalized Digital Healthcare
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS accelerates AI-powered care with new tech leadership, personalized treatments and a major $870 million investment push.
Read More
Hims & Hers Q3 Preview: Key Metrics I Want To See For Beating 2030 Guidance
Published: October 21, 2025 by: Seeking Alpha
Sentiment: Positive
I expect Hims & Hers Health, Inc. to show stabilizing ARPU around $54+ per user in Q3 despite the GLP-1 slowdown, which could signal meaningful upside to the company's conservative 2030 guidance. I'm anticipating a slight margin dip in Q3. Margins should then stabilize thanks to 1-3% annual marketing leverage gains that support subscriber growth without added costs. In my view, HIMS is already surpassing implied 2030 ARPU targets, and expansions into menopause, hormone health, and personalized plans will help it beat guidance ahead of time.
Read More
Hims & Hers: Q3 Could Provide Volatility, But The Long-Term Vision Remains Bright
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers (HIMS) is emerging as a disruptive force in the obesity treatment market, challenging established GLP-1 drug makers. HIMS has aggressively captured market share, often operating in a legal 'grey area' regarding compounded obesity drugs. Recent FDA policy changes ending temporary compounding allowances raise questions about HIMS's continued ability to offer these treatments.
Read More
Hims & Hers Health: Roller Coaster Gift
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health launched menopause and low testosterone products in the last month, expanding its addressable market and supporting its $6.5 billion 2030 revenue target. Recent product launches, including at-home lab testing, are expected to boost ARPU and drive significant revenue growth for HIMS in coming years. The stock market over reacted to planned stock sells by the CEO.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Medical - Equipment & Services
- CEO Andrew Dudum
- Employees 1637